Quantitative Investment Management LLC Makes New $992,000 Investment in United Therapeutics Corporation $UTHR

Quantitative Investment Management LLC bought a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 1,831 shares of the biotechnology company’s stock, valued at approximately $992,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Toth Financial Advisory Corp boosted its position in shares of United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 48 shares in the last quarter. Fiduciary Financial Advisors bought a new position in United Therapeutics in the second quarter worth $30,000. Entrust Financial LLC bought a new position in United Therapeutics in the fourth quarter worth $31,000. Caitlin John LLC purchased a new position in United Therapeutics during the second quarter valued at $37,000. Finally, International Assets Investment Management LLC lifted its position in United Therapeutics by 426.7% during the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 64 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, August 31st. The stock was sold at an average price of $511.09, for a total value of $4,855,355.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $165,819,572.87. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $523.14, for a total value of $4,342,062.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at $23,631,280.08. This represents a 15.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 414,075 shares of company stock valued at $221,222,045 in the last three months. 8.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on UTHR. Royal Bank Of Canada reduced their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. JPMorgan Chase & Co. lifted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research note on Thursday, August 6th. Bank of America cut their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $512.70 on Wednesday. The firm has a market cap of $21.99 billion, a P/E ratio of 18.34, a P/E/G ratio of 2.55 and a beta of 0.56. United Therapeutics Corporation has a fifty-two week low of $375.61 and a fifty-two week high of $609.35. The firm has a 50-day simple moving average of $529.27 and a two-hundred day simple moving average of $539.68.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.41 earnings per share. On average, equities research analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.